During the recent session, F-star Therapeutics Inc. (NASDAQ:FSTX)’s traded shares were 5.42 million, with the beta value of the company hitting 1.67. At the last check today, the stock’s price was $6.32, reflecting an intraday gain of 58.79% or $2.34. The 52-week high for the FSTX share is $9.52, that puts it down -50.63 from that peak though still a striking 67.25% gain since the share price plummeted to a 52-week low of $2.07. The company’s market capitalization is $82.07M, and the average intraday trading volume over the past 10 days was 0.21 million shares, and the average trade volume was 139.21K shares over the past three months.
F-star Therapeutics Inc. (FSTX) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.40. FSTX has a Sell rating from 0 analyst(s) out of 7 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.6.
F-star Therapeutics Inc. (NASDAQ:FSTX) trade information
F-star Therapeutics Inc. (FSTX) registered a 58.79% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 58.79% in intraday trading to $6.32 this Wednesday, 06/22/22, hitting a weekly high. The stock’s 5-day price performance is 14.70%, and it has moved by 57.31% in 30 days. Based on these gigs, the overall price performance for the year is -57.97%. The short interest in F-star Therapeutics Inc. (NASDAQ:FSTX) is 0.2 million shares and it means that shorts have 1.73 day(s) to cover.
The consensus price target of analysts on Wall Street is $27.33, which implies an increase of 76.88% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $15.00 and $35.00 respectively. As a result, FSTX is trading at a discount of -453.8% off the target high and -137.34% off the low.
F-star Therapeutics Inc. (FSTX) estimates and forecasts
Statistics show that F-star Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. F-star Therapeutics Inc. (FSTX) shares have gone down -23.31% during the last six months, with a year-to-date growth rate less than the industry average at -25.00% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 34.80% this quarter and then drop -28.80% in the quarter after that. In the rating firms’ projections, revenue will decrease -70.00% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.73 million as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $1.39 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 27.80%. While earnings are projected to return 80.60% in 2022.
F-star Therapeutics Inc. is due to release its next quarterly earnings between March 28 and April 01. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
F-star Therapeutics Inc. (NASDAQ:FSTX)’s Major holders
F-star Therapeutics Inc. insiders own 4.22% of total outstanding shares while institutional holders control 54.84%, with the float percentage being 57.25%. Ridgeback Capital Investments L.P. is the largest shareholder of the company, while 47 institutions own stock in it. As of Dec 30, 2021, the company held over 1.83 million shares (or 8.51% of all shares), a total value of $9.21 million in shares.
The next largest institutional holding, with 0.98 million shares, is of Point72 Asset Management, L.P.’s that is approximately 4.55% of outstanding shares. At the market price on Dec 30, 2021, these shares were valued at $4.93 million.
Also, the Mutual Funds coming in first place with the largest holdings of F-star Therapeutics Inc. (FSTX) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Dec 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 0.43 million shares. This amounts to just over 1.98 percent of the company’s overall shares, with a $2.15 million market value. The same data shows that the other fund manager holds slightly less at 0.29 million, or about 1.33% of the stock, which is worth about $1.44 million.